Vertex Pharmaceuticals Inc
NASDAQ:
VRTX
-
Vertex Pharmaceuticals Inc
-
Sector
Health Care
-
Industry
Biotechnology
-
Company web
Link
-
Employees
Full Time Employees: 2,150
-
Executives
- Jeffrey Leiden
- Thomas Graney
- Ian Smith
- Michael Parini
- David Altshuler
- Stuart Arbuckle
- Jeffrey Chodakewitz
- Amit Sachdev
- Paul Silva
- Bruce Sachs
-
Company address
- 50 Northern Avenue
- Boston, MA 02210
- United States of America
- 1-617-341-6100
-
Investor Relation Site
Link
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Vertex Pharmaceuticals Inc: Slide deck
- VRTX-Third-Quarter 2017 Financial Results October 2017: Slides deck
- VRTX-Third Quarter 2016 Financial Results October 25, 2016: Slides deck
- VRTX-Second-Quarter 2017 Financial Results July 2017: Slides deck
- VRTX-First-Quarter 2017 Financial Results April 2017: Slides deck
- VRTX-Full-Year and Fourth-Quarter 2016 Financial Results January 2017: Slides deck